{"id":390313,"date":"2019-12-11T00:00:00","date_gmt":"2019-12-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0007-2019-biopharma-non-small-cell-lung-cancer-unmet-need-us-eu-2019\/"},"modified":"2026-03-31T10:45:58","modified_gmt":"2026-03-31T10:45:58","slug":"unneon0007-2019-biopharma-non-small-cell-lung-cancer-unmet-need-us-eu-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0007-2019-biopharma-non-small-cell-lung-cancer-unmet-need-us-eu-2019\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Unmet Need | US\/EU | 2019"},"content":{"rendered":"<p><em>EGFR<\/em>-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven targeted therapies in this indication. EGFR tyrosine kinase inhibitors (TKIs)\u2014Tarceva (Roche\/ Genentech), Iressa (AstraZeneca), Tagrisso (AstraZeneca), and Gilotrif\/Giotrif (Boehringer Ingelheim)\u2014have been the conventional first-line choice of therapy in <em>EGFR<\/em>-mutation-positive metastatic nonsquamous\u00a0NSCLC for many years. In 2018, the next-generation EGFR\u00a0TKI Vizimpro (Pfizer) was approved in the United States for the first-line treatment of patients with <em>EGFR<\/em>\u00a0mutations. The PD-1 inhibitor Opdivo (Bristol-Myers Squibb)\u00a0for treatment of <em>EGFR<\/em>-mutation-positive\u00a0metastatic nonsquamous\u00a0NSCLC is another option for patients who have progressed on EGFR\u00a0TKIs. However, resistance to EGFR\u00a0TKIs and treatment-related adverse events remain key unmet needs in the metastatic setting, generating opportunity for novel therapies to gain an upper hand over the existing drugs in the NSCLC treatment landscape.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for\u00a0<em>EGFR<\/em>-mutation-positive metastatic nonsquamous\u00a0NSCLC?<\/li>\n<li>How do current therapies, such as Opdivo, perform on key treatment drivers and goals for <em>EGFR<\/em>-mutation-positive metastatic nonsquamous\u00a0NSCLC?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <em>EGFR<\/em>-mutation-positive metastatic nonsquamous\u00a0NSCLC?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to surveyed oncologists for hypothetical new treatment options in first-line <em>EGFR<\/em>-mutation-positive metastatic nonsquamous\u00a0NSCLC?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany.<\/p>\n<p><strong>Primary research: <\/strong> Survey of 61\u00a0medical oncologists in US and 30 medical oncologists in Europe fielded in March 2019.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Pfizer,\u00a0Teva.<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Tarceva, Iressa, Gilotrif\/Giotrif, Tagrisso, Vizimpro, Avastin (in combination with\u00a0paclitaxel\u00a0and\u00a0carboplatin),\u00a0Opdivo.<\/p>\n","protected":false},"template":"","class_list":["post-390313","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390313\/revisions"}],"predecessor-version":[{"id":393438,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390313\/revisions\/393438"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}